Sector
PharmaceuticalsOpen
₹23Prev. Close
₹23.15Turnover(Lac.)
₹7.77Day's High
₹23.82Day's Low
₹2352 Week's High
₹41.252 Week's Low
₹19Book Value
₹19.27Face Value
₹10Mkt Cap (₹ Cr.)
115.68P/E
0EPS
0Divi. Yield
02 Sep 2023
12:00 AM
AGM
Announcement Date: 02 Sep, 2023
24 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
5 Sep 2023
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 50.1 | 50.1 | 40.67 | 40.67 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 68.18 | 107.78 | 118.24 | 100.79 |
Net Worth | 118.28 | 157.88 | 158.91 | 141.46 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Revenue | 202.37 | 167.25 | 169.57 | 243.52 |
yoy growth (%) | 20.99 | -1.36 | -30.36 | 22.52 |
Raw materials | -112.35 | -94.65 | -127.94 | -171.5 |
As % of sales | 55.51 | 56.59 | 75.45 | 70.42 |
Employee costs | -14.01 | -13.41 | -11.73 | -10.27 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 29.49 | 4.73 | -16.1 | 15.23 |
Depreciation | -15.82 | -17.33 | -19.3 | -18.16 |
Tax paid | -6.71 | -1.1 | 4.07 | -2.89 |
Working capital | 9.02 | 16.64 | -30.71 | 3.77 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 20.99 | -1.36 | -30.36 | 22.52 |
Op profit growth | 57.67 | 169.55 | -73.11 | -9.21 |
EBIT growth | 144.96 | -414.59 | -115.35 | -33.57 |
Net profit growth | 527.76 | -130.15 | -197.49 | 422.36 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,587.35 | 124.83 | 3,80,990.4 | 867.6 | 0.85 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,534.8 | 76.42 | 1,20,383.36 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,490 | 32.38 | 1,20,295.96 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,154.55 | 33.79 | 1,16,159.65 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,770.9 | 26.36 | 1,12,931.2 | 1,034.8 | 0.59 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Omkar P Herlekar
Whole-time Director
Shivanand Hedge
Independent Director
Hardesh Tolani
Independent Director
Ajay Sukhwani
Independent Director
Ekta Gurnasinghani
Company Sec. & Compli. Officer
Mitti M Jain
Independent Director
Manali Bhagtani
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Lasa Supergenerics Ltd
Summary
Lasa Supergenerics Limited was incorporated on March 11, 2016. The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing. The Company is a veterinary API manufacturing entity, which was acquired in April, 2012. The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra. It specialises in catalyst chemistry and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India. To efficiently control the supply chain, the Company is fully backward integrated for its key molecules-from discovery research up to full-scale bulk production. The Companys marketing footprint is entrenched across developing markets in multiple countries. Similarly, the group expects to augment its export footprint significantly in width and depth in the future.The Company announced the launching of 2 new block buster products with all-time strong segment, Oxycozanide. Oxyclozanide is an anthelmintic, used in the treatment and control of fascioliasis a topical worm infection in ruminants mainly domestic animals such as cattle, especially buffalos in farm, sheep, and goats. For this, the Comp
Read More
What is the Lasa Supergenerics Ltd share price today?
The Lasa Supergenerics Ltd shares price on N/A is Rs.₹23.01 today.
What is the Market Cap of Lasa Supergenerics Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Lasa Supergenerics Ltd is ₹115.28 Cr. as of 23 Jul ‘24
What is the PE and PB ratio of Lasa Supergenerics Ltd?
The PE and PB ratios of Lasa Supergenerics Ltd is 0 and 1.19 as of 23 Jul ‘24
What is the 52 Week High and Low of Lasa Supergenerics Ltd?
The 52-week high/low is the highest and lowest price at which a Lasa Supergenerics Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Lasa Supergenerics Ltd is ₹19 and ₹40.95 as of 23 Jul ‘24
What is the CAGR of Lasa Supergenerics Ltd?
Lasa Supergenerics Ltd's CAGR for 5 Years at 14.49%, 3 Years at -35.57%, 1 Year at 6.32%, 6 Month at -27.77%, 3 Month at -10.52% and 1 Month at 0.00%.
What is the shareholding pattern of Lasa Supergenerics Ltd?
The shareholding pattern of Lasa Supergenerics Ltd is as follows:
Promoters - 53.65 %
Institutions - 0.00 %
Public - 46.35 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
